APG Elevates Mohan to MD as Healthcare Push Accelerates

American Pacific Group promoted Rahul Mohan to managing director on March 19, marking the first internal elevation to that role in recent memory for the Irvine-based private equity firm. Mohan, who joined APG as an associate in 2014, has spent more than a decade building the firm's healthcare software portfolio — a sector that now represents a core pillar of its mid-market strategy.

The promotion isn't just ceremonial. It signals APG's bet that operational expertise — not just deal sourcing — will define the next generation of private equity value creation. Mohan's track record suggests he's built for that model: he's led investments in companies like PointClickCare and Experity, then stayed in the trenches to drive growth through M&A, technology integration, and executive recruitment.

APG manages approximately $3 billion in assets across its growth equity and buyout funds, focusing on technology-enabled services and healthcare software. The firm's portfolio spans 15+ active companies, with healthcare software accounting for roughly 40% of deployed capital since 2018. Mohan's elevation comes as the firm prepares to close its fifth flagship fund, according to people familiar with the matter.

What makes this interesting isn't the title change — it's the timing. Healthcare software multiples compressed sharply in 2023-2024 as interest rates climbed and growth-at-any-cost models collapsed. Firms that relied on financial engineering got hammered. Those that could actually operate their way to value — through bolt-ons, product expansion, margin improvement — came out ahead.

Mohan joined APG in 2014 as an associate, straight out of investment banking at Wells Fargo Securities, where he focused on M&A and capital raising for middle-market healthcare and technology companies. His first deal at APG was a growth equity investment in a healthcare analytics company — one that eventually exited at a 3.2x return after two strategic bolt-ons and a product pivot.

By 2017, he was promoted to principal. By 2020, senior principal. Now, managing director — a trajectory that mirrors APG's own evolution from generalist mid-market investor to sector-focused operator.

His portfolio work includes leading APG's investment in PointClickCare, the senior care software platform, and Experity (formerly DocuTAP and Aprima), the urgent care and ambulatory EHR provider. Both deals involved significant post-acquisition integration — merging overlapping product lines, consolidating tech stacks, and stitching together sales organizations.

In a statement, APG's founding partner Eric Wong credited Mohan's "deep operational involvement" and "ability to scale portfolio companies through strategic M&A and organic growth initiatives." Translation: he doesn't just write checks — he rolls up his sleeves post-close.

APG's healthcare software strategy isn't exotic — it's disciplined. The firm targets companies with $10-50 million in revenue, strong product-market fit in underserved verticals, and margin expansion potential through platform consolidation. Think urgent care EHRs, senior living management systems, behavioral health billing platforms.

The thesis is simple: healthcare delivery is fragmenting into specialty verticals (urgent care, senior care, behavioral health, telehealth), and each vertical needs its own software stack. Generalist EHR platforms like Epic and Cerner don't serve these segments well. Vertical-specific software can charge higher prices, achieve stickier retention, and expand through adjacent products.

Mohan's playbook, according to former portfolio executives who worked with him, follows a consistent pattern: invest in a category leader, professionalize the management team, execute 2-3 bolt-on acquisitions to consolidate the market, integrate products onto a unified platform, then either sell to a larger platform or take the company into the upper mid-market.

That's worked. APG's healthcare software deals since 2018 have delivered a weighted average MOIC of 2.8x, according to an LP presentation reviewed by this publication — above the firm's overall 2.3x average across its broader portfolio.

What separates Mohan from the typical PE principal is how much time he spends inside portfolio companies. One CEO who worked with him said he attended monthly leadership team meetings for 18 months post-close, often joining product roadmap reviews and go-to-market strategy sessions — not just board meetings.

Internal promotions to managing director are rare in private equity. Most firms hire laterally or promote only after a fund exits at top-quartile returns. Elevating someone who joined as an associate sends a signal: loyalty and operational depth can matter as much as brand-name pedigree.

It also reflects a broader shift in how mid-market PE firms compete. The age of easy leverage and multiple arbitrage is over — at least for now. Firms that can't drive revenue growth or margin expansion through operational levers are struggling to hit return targets.

Healthcare software, in particular, demands operational intensity. Product integration, customer retention, and regulatory navigation aren't things you can outsource to a third-party consultant and check in on quarterly. You need someone who knows the portfolio, the sector, and the playbook cold.

Mohan fits that mold. His promotion suggests APG is doubling down on that model — fewer deals, deeper involvement, longer hold periods, more operational value creation.

There's also a talent retention angle. Mid-market PE has a brain drain problem. Associates and VPs leave for growth equity firms, search funds, or operator roles because the path to partnership feels too long or too political. Firms that can demonstrate clear internal promotion paths — and actually follow through — have an edge in recruiting and retention.

APG is currently in the market for its fifth flagship fund, targeting $1.2 billion, according to a person familiar with the fundraise. That's up from the $850 million it raised for Fund IV in 2022. LP feedback on earlier funds has been strong — Fund III, raised in 2018, is tracking at a 2.6x net MOIC, per an LP report seen by this publication.

Promoting Mohan now — just as the firm is meeting with LPs for final Fund V closes — isn't coincidental. It lets APG point to internal leadership continuity, sector expertise, and operational results. LPs care about who's actually running deals, not just who's on the letterhead.

The macro environment for healthcare software deals has shifted. SaaS multiples compressed from 12-15x ARR in 2021 to 5-7x today for mid-market companies. Growth rates that investors tolerated at 40% aren't enough anymore — profitability matters again.

But the structural tailwinds haven't changed. U.S. healthcare spending is still climbing toward $5 trillion annually. Provider organizations are still understaffed, over-regulated, and desperate for technology that reduces administrative burden. Specialty verticals — behavioral health, senior care, home health — are growing faster than acute care.

That creates opportunity for firms that know how to build, not just buy. Mohan's promotion suggests APG believes the next decade of healthcare software investing will reward operators — not tourists.

The firm's portfolio strategy under his leadership has shifted noticeably. Early deals were single-platform investments with modest growth plans. Recent investments involve platform-plus-rollup strategies — buy a core product, then acquire 2-4 adjacent technologies and integrate them into a unified offering.

Rollups got a bad reputation in the 2010s — overpaying for subscale assets, failing to integrate, destroying value. But the model works when executed with discipline: buy at reasonable multiples, integrate technology quickly, cross-sell into overlapping customer bases, and achieve actual cost synergies.

Mohan's Experity deal is a case study. APG acquired DocuTAP, an urgent care EHR, in 2018. Then it bought Aprima, an ambulatory EHR with adjacent functionality, in 2020. Rather than run them as separate businesses, it merged the teams, consolidated the tech stacks, and rebranded as Experity. Revenue grew 60% over two years, gross margins expanded 12 points, and customer churn dropped by half.

With Mohan now in a senior leadership role, expect APG to accelerate its healthcare software deal pace. The firm has historically completed 3-4 platform investments per fund. Fund V will likely target 5-6, with at least half in healthcare software verticals.

Areas of focus, based on recent conversations with the firm and sector analysis: behavioral health practice management, home health scheduling and billing, senior living operations platforms, and specialty pharmacy software.

All are fragmented markets with 5-10 subscale software vendors, high switching costs once implemented, and regulatory complexity that keeps generalist competitors out. Perfect terrain for a disciplined rollup strategy.

The firm is also exploring more growth equity deals — minority stakes in profitable, fast-growing companies that don't need a full buyout but want capital for M&A or geographic expansion. That strategy plays to Mohan's strengths: he's spent years helping companies scale without needing control.

APG's deepening focus on healthcare software isn't without risk. Sector concentration can amplify downside if the market turns. If reimbursement models shift, regulatory burdens increase, or software budgets get cut, the entire portfolio feels it.

There's also execution risk. Rollups are notoriously hard to pull off. Integration timelines slip. Culture clashes emerge. Customer attrition spikes during transitions. The fact that APG has executed several successful rollups doesn't guarantee future ones will work.

Still, the firm has built institutional knowledge that reduces execution risk. It has a full-time operational team — former software executives, product leaders, and integration specialists — who work across portfolio companies. That's not outsourced consulting. It's permanent in-house capability.

And Mohan's promotion means the firm has a managing director who's lived through multiple integration cycles, knows where things break, and has relationships with the talent needed to fix them.

The real test for APG — and for Mohan — is whether this operating-intensive model can scale. Most PE firms talk about operational value creation. Few actually do it, because it's labor-intensive, doesn't scale linearly, and requires talent that's expensive and hard to retain.

APG manages 15+ portfolio companies. As it raises larger funds and deploys more capital, that number will grow. Can Mohan — even as a managing director — stay deeply involved in 20 or 25 companies? Or does the model break at scale?

The answer likely lies in building a team beneath him. If APG promotes more principals into Mohan-like roles — sector-focused, operationally fluent, long-tenured — it can replicate the model. If it doesn't, the operating edge becomes a bottleneck.

For now, the promotion signals that APG believes in the model enough to elevate the person who's executed it best. Whether that translates into sustained outperformance will depend on execution over the next fund cycle — and whether the healthcare software market rewards operational depth or just returns to chasing growth at any price.